Nine companies pitched at the Investors Forum during the Dutch Life Sciences Conference, 24th November in Leiden and only one could be the winner.
STENTiT developes a unique technological platform that shapes the first-of-its-kind regenerative stents.
Check out more about the DLSC Investor Forum and about the investors who were present: www.dutchlifesciences.com/investors-forum
Link to the STENTiT newsitem about the DLSC Investor Forum.
STENTiT was one of the Venture Challenge Fall 2016 teams.
The STENTiT regenerative stent will be the only device on the market that brings vascular regeneration to the patient without requiring invasive surgical procedures. Made out of a fully biodegradable porous structure, the product provides minimally-invasive support to the diseased artery and promotes natural vascular regeneration using the patient’s circulating blood cells.
More about STENTiT check their website at www.stentit.com